-
1
-
-
0028157044
-
Pathogenesis of multiple sclerosis
-
ffrench-Constant C. Pathogenesis of multiple sclerosis. Lancet 1994;343:271-275
-
(1994)
Lancet
, vol.343
, pp. 271-275
-
-
Ffrench-Constant, C.1
-
2
-
-
67649430621
-
-
Accessed December 19, 2008
-
National MS Society Information Sourcebook: Epidemiology. National Multiple Sclerosis Society Web site. http://main.nationalmssociety.org/docs/HOM/ epidemiology.pdf. Accessed December 19, 2008
-
National MS Society Information Sourcebook: Epidemiology
-
-
-
7
-
-
0027418515
-
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
-
The IFNB Multiple Sclerosis Study Group
-
The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661
-
(1993)
Neurology
, Issue.43
, pp. 655-661
-
-
-
8
-
-
0029082566
-
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial
-
The Copolymer Multiple Sclerosis Study Group
-
Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer Multiple Sclerosis Study Group. Neurology 1995;45:1268-1276
-
(1995)
Neurology
, vol.45
, pp. 1268-1276
-
-
Johnson, K.P.1
Brooks, B.R.2
Cohen, J.A.3
-
9
-
-
0008678962
-
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
-
DOI 10.1002/ana.410390304
-
Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294 (Pubitemid 26100751)
-
(1996)
Annals of Neurology
, vol.39
, Issue.3
, pp. 285-294
-
-
Jacobs, L.D.1
Cookfair, D.L.2
Rudick, R.A.3
Herndon, R.M.4
Richert, J.R.5
Salazar, A.M.6
Fischer, J.S.7
Goodkin, D.E.8
Granger, C.V.9
Simon, J.H.10
Alam, J.J.11
Bartoszak, D.M.12
Bourdette, D.N.13
Braiman, J.14
Brownscheidle, C.M.15
Coats, M.E.16
Cohan, S.L.17
Dougherty, D.S.18
Kinkel, R.P.19
Mass, M.K.20
Munschauer III, F.E.21
Priore, R.L.22
Pullicino, P.M.23
Scherokman, B.J.24
Weinstock-Guttman, B.25
Whitham, R.H.26
more..
-
10
-
-
0345601517
-
Randomised double-blind placebo-controlled study of interferon beta-in relapsing/remitting multiple sclerosis
-
PRISMS (Prevention of Relapses and Disability by Interferon beta-Subcutaneously in Multiple Sclerosis) Study Group
-
PRISMS (Prevention of Relapses and Disability by Interferon beta-Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504
-
(1998)
Lancet
, vol.352
, pp. 1498-1504
-
-
-
12
-
-
33644584352
-
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
-
DOI 10.1056/NEJMoa044397
-
Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910 (Pubitemid 43313657)
-
(2006)
New England Journal of Medicine
, vol.354
, Issue.9
, pp. 899-910
-
-
Polman, C.H.1
O'Connor, P.W.2
Havrdova, E.3
Hutchinson, M.4
Kappos, L.5
Miller, D.H.6
Phillips, J.T.7
Lublin, F.D.8
Giovannoni, G.9
Wajgt, A.10
Toal, M.11
Lynn, F.12
Panzara, M.A.13
Sandrock, A.W.14
-
13
-
-
33644605483
-
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
-
DOI 10.1056/NEJMoa054693
-
Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation for progressive multifocal leukoencephalopathy in natalizumab treated patients. N Engl J Med 2006;354:924-933 (Pubitemid 43313659)
-
(2006)
New England Journal of Medicine
, vol.354
, Issue.9
, pp. 924-933
-
-
Yousry, T.A.1
Major, E.O.2
Ryschkewitsch, C.3
Fahle, G.4
Fischer, S.5
Hou, J.6
Curfman, B.7
Miszkiel, K.8
Mueller-Lenke, N.9
Sanchez, E.10
Barkhof, F.11
Radue, E.-W.12
Jager, H.R.13
Clifford, D.B.14
-
14
-
-
46849108700
-
Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden
-
DOI 10.1177/1352458507086667
-
Kobelt G, Berg J, Lindgren P, et al. Modeling the cost effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult Scler 2008;14:679-690 (Pubitemid 351954411)
-
(2008)
Multiple Sclerosis
, vol.14
, Issue.5
, pp. 679-690
-
-
Kobelt, G.1
Berg, J.2
Lindgren, P.3
Jonsson, B.4
Stawiarz, L.5
Hillert, J.6
-
15
-
-
45849092934
-
Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK
-
DOI 10.2165/00019053-200826070-00008
-
Gani R, Giovannoni G, Bates D, et al. Cost effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics 2008;26:617-627 (Pubitemid 351876727)
-
(2008)
PharmacoEconomics
, vol.26
, Issue.7
, pp. 617-627
-
-
Gani, R.1
Giovannoni, G.2
Bates, D.3
Kemball, B.4
Hughes, S.5
Kerrigan, J.6
-
17
-
-
35748930835
-
-
Issued January Accessed December 19, 2008
-
Multiple sclerosis - beta interferon and glatiramer acetate. National Institute for Health and Clinical Excellence (NICE) Web site. http://www.nice.org.uk/Guidance/TA32. Issued January 2002. Accessed December 19, 2008
-
(2002)
Multiple Sclerosis - Beta Interferon and Glatiramer Acetate
-
-
-
18
-
-
9444223856
-
End-stage renal disease-associated managed care costs among patients with and without diabetes
-
DOI 10.2337/diacare.27.12.2829
-
Joyce AT, Iacoviello JM, Nag S, et al. End-stage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care 2004;27:2829-2835 (Pubitemid 39565045)
-
(2004)
Diabetes Care
, vol.27
, Issue.12
, pp. 2829-2835
-
-
Joyce, A.T.1
Iacoviello, J.M.2
Nag, S.3
Sajjan, S.4
Jilinskaia, E.5
Throop, D.6
Pedan, A.7
Ollendorf, D.A.8
Alexander, C.M.9
-
19
-
-
1042288307
-
Medicare Program Expenditures Associated with Hospice Use
-
Campbell DE, Lynn J, Louis TA, et al. Medicare program expenditures associated with hospice use. Ann Intern Med 2004;140:269-277 (Pubitemid 38200534)
-
(2004)
Annals of Internal Medicine
, vol.140
, Issue.4
, pp. 269-277
-
-
Campbell, D.E.1
Lynn, J.2
Louis, T.A.3
Shugarman, L.R.4
-
20
-
-
6344258263
-
The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans
-
DOI 10.1016/S0149-2918(04)80225-X, PII S014929180480225X
-
Ozminkowski RJ, Marder WD, Hawkins K, et al. The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans. Clin Ther 2004;26:1341-1354 (Pubitemid 39420318)
-
(2004)
Clinical Therapeutics
, vol.26
, Issue.8
, pp. 1341-1354
-
-
Ozminkowski, R.J.1
Marder, W.D.2
Hawkins, K.3
Wang, S.4
Stallings, S.C.5
Finkelstein, S.N.6
Sinskey, A.J.7
Wierz, D.8
-
21
-
-
0028140558
-
Impairment, disability, and handicap in multiple sclerosis: A population-based study in Olmsted County, Minnesota
-
Rodriguez M, Siva A, Ward J, et al. Impairment, disability, and handicap in multiple sclerosis: A population-based study in Olmsted County, Minnesota. Neurology 2004;44:28-33
-
(2004)
Neurology
, vol.44
, pp. 28-33
-
-
Rodriguez, M.1
Siva, A.2
Ward, J.3
-
22
-
-
67649455674
-
-
MAG Mutual Healthcare Solutions, Inc., Duluth, GA
-
2008 Physicians' Fee and Coding Guide. MAG Mutual Healthcare Solutions, Inc., Duluth, GA
-
2008 Physicians' Fee and Coding Guide
-
-
-
23
-
-
0036151499
-
Cost perspectives for outpatient intravenous antimicrobial therapy
-
Tice AD, Hoaglund PA, Nolet B, et al. Cost perspectives for outpatient intravenous antimicrobial therapy. Pharmacotherapy 2002;22:63-70S (Pubitemid 34112873)
-
(2002)
Pharmacotherapy
, vol.22
, Issue.2
-
-
Tice, A.D.1
Hoaglund, P.A.2
Nolet, B.3
McKinnon, P.S.4
Mozaffari, E.5
-
24
-
-
59249093995
-
Utilization of health care by patients with multiple sclerosis is based on professional and patient-defined health needs
-
Beckerman H, van Zee IE, de Groot V, et al. Utilization of health care by patients with multiple sclerosis is based on professional and patient-defined health needs. Mult Scler 2008;14:1269-1279
-
(2008)
Mult Scler
, vol.14
, pp. 1269-1279
-
-
Beckerman, H.1
Van Zee, I.E.2
De Groot, V.3
-
25
-
-
3042739652
-
4-integrin antagonist selective adhesion molecule inhibitors for MS
-
DOI 10.1586/14737175.4.4.571
-
Rudick R, Sandrock AW. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurotherapeutics 2004;4:571-580 (Pubitemid 38890585)
-
(2004)
Expert Review of Neurotherapeutics
, vol.4
, Issue.4
, pp. 571-580
-
-
Rudick, R.A.1
Sandrock, A.2
-
26
-
-
0034955141
-
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
-
DOI 10.1002/ana.1032
-
McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127 (Pubitemid 32591472)
-
(2001)
Annals of Neurology
, vol.50
, Issue.1
, pp. 121-127
-
-
Buckley, C.1
Douek, D.2
Newsom-Davis, J.3
Vincent, A.4
Willcox, N.5
-
27
-
-
3042781524
-
Cost of managing an episode of relapse in multiple sclerosis in the United States
-
DOI 10.1186/1472-6963-3-1, 17
-
O'Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003;3:17-28 (Pubitemid 38865232)
-
(2003)
BMC Health Services Research
, vol.3
, pp. 1-12
-
-
O'Brien, J.A.1
Ward, A.J.2
Patrick, A.R.3
Caro, J.4
-
28
-
-
0003617159
-
-
US Bureau of Labor Statistics. Washington, DC: US Bureau of Labor Statistics; January 16, Publication USDL-03-15
-
US Bureau of Labor Statistics. Consumer Price Index: December 2002. Washington, DC: US Bureau of Labor Statistics; January 16, 2003. Publication USDL-03-15
-
(2003)
Consumer Price Index: December 2002
-
-
-
29
-
-
67649448235
-
-
US Bureau of Labor Statistics. Washington, DC: US Bureau of Labor Statistics; November 16, Publication USDL-06-1979
-
US Bureau of Labor Statistics. Consumer Price Index: October 2006. Washington, DC: US Bureau of Labor Statistics; November 16, 2006. Publication USDL-06-1979
-
(2006)
Consumer Price Index: October 2006
-
-
-
30
-
-
37449008267
-
The immunogenicity of disease-modifying therapies for multiple sclerosis: Clinical implications for neurologists
-
Fox EJ, Vartanian TK, Zamvil SS. The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists. Neurologist 2007;13:355-362
-
(2007)
Neurologist
, vol.13
, pp. 355-362
-
-
Fox, E.J.1
Vartanian, T.K.2
Zamvil, S.S.3
-
31
-
-
67649448239
-
-
Factors that influence adherence with disease-modifying therapy in multiple sclerosis. Poster presented at
-
Treadaway K, Brannon K, Morrison A, et al. Factors that influence adherence with disease-modifying therapy in multiple sclerosis. Poster presented at: 58th Annual Meeting of the American Academy of Neurology; April 1-8, 2006; San Diego, CA
-
58th Annual Meeting of the American Academy of Neurology; April 1-8, 2006; San Diego, CA
-
-
Treadaway, K.1
Brannon, K.2
Morrison, A.3
-
32
-
-
13844315516
-
Stopping beta-interferon therapy in multiple sclerosis: An analysis of stopping patterns
-
DOI 10.1191/1352458505ms1131oa
-
O'Rourke KET, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46-50 (Pubitemid 40259974)
-
(2005)
Multiple Sclerosis
, vol.11
, Issue.1
, pp. 46-50
-
-
O'Rourke, K.E.T.1
Hutchinson, M.2
-
33
-
-
0347599145
-
Long-term interferon-β treatment for multiple sclerosis
-
DOI 10.1007/s10072-003-0190-3
-
Ruggieri RM, Settipani N, Viviano L, et al. Long-term interferon-β treatment for multiple sclerosis. Neurol Sci 2003;24:361-364 (Pubitemid 38029025)
-
(2003)
Neurological Sciences
, vol.24
, Issue.5
, pp. 361-364
-
-
Ruggieri, R.M.1
Settipani, N.2
Viviano, L.3
Attanasio, M.4
Giglia, L.5
Almasio, P.6
La Bella, V.7
Piccoli, F.8
-
34
-
-
67649297820
-
Quantitative riskbenefit analysis of natalizumab
-
Thompson JP, Noyes K, Dorsey ER, et al. Quantitative riskbenefit analysis of natalizumab. Neurology 2008;71:357-364
-
(2008)
Neurology
, vol.71
, pp. 357-364
-
-
Thompson, J.P.1
Noyes, K.2
Dorsey, E.R.3
|